321 related articles for article (PubMed ID: 34905550)
1. Nationwide screening for Fabry disease in unselected stroke patients.
Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
[TBL] [Abstract][Full Text] [Related]
4. [Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].
Alfano G; Ganda N; Cerami C; Mori G; Fontana F; Cappelli G
G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582965
[TBL] [Abstract][Full Text] [Related]
5. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
6. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
7. Screening for Fabry Disease in Japanese Patients with Young-Onset Stroke by Measuring α-Galactosidase A and Globotriaosylsphingosine.
Kinoshita N; Hosomi N; Matsushima H; Nakamori M; Yagita Y; Yamawaki T; Torii T; Kitamura T; Sueda Y; Shimomura R; Araki M; Nezu T; Aoki S; Ishii S; Maruyama H; Matsumoto M; Maruyama H
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3563-3569. PubMed ID: 30201457
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients.
Baptista MV; Ferreira S; Pinho-E-Melo T; Carvalho M; Cruz VT; Carmona C; Silva FA; Tuna A; Rodrigues M; Ferreira C; Pinto AA; Leitão A; Gabriel JP; Calado S; Oliveira JP; Ferro JM;
Stroke; 2010 Mar; 41(3):431-6. PubMed ID: 20110537
[TBL] [Abstract][Full Text] [Related]
9. Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience.
Gragnaniello V; Burlina AP; Polo G; Giuliani A; Salviati L; Duro G; Cazzorla C; Rubert L; Maines E; Germain DP; Burlina AB
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34199132
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
[TBL] [Abstract][Full Text] [Related]
11. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
[TBL] [Abstract][Full Text] [Related]
14. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
[TBL] [Abstract][Full Text] [Related]
15. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic.
Zemánek D; Januška J; Honěk T; Čurila K; Kubánek M; Šindelářová Š; Zahálková L; Klofáč P; Laštůvková E; Lichnerová E; Aiglová R; Lhotský J; Vondrák J; Dostálová G; Táborský M; Kasper D; Linhart A
ESC Heart Fail; 2022 Dec; 9(6):4160-4166. PubMed ID: 36087038
[TBL] [Abstract][Full Text] [Related]
16. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
18. Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.
Delarosa-Rodríguez R; Santotoribio JD; Paula HA; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
Clin Genet; 2021 Jun; 99(6):761-771. PubMed ID: 33527381
[TBL] [Abstract][Full Text] [Related]
19. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease due to D313Y and novel GLA mutations.
Koulousios K; Stylianou K; Pateinakis P; Zamanakou M; Loules G; Manou E; Kyriklidou P; Katsinas C; Ouzouni A; Kyriazis J; Speletas M; Germenis AE
BMJ Open; 2017 Oct; 7(10):e017098. PubMed ID: 28988177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]